hotspot -WSS

hotspot

author：fashion 2025-09-28 02:28:04 - browse：91342

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Brain MRIs reveal impact of 'toxic stress' on Black children

leisure time

WSS

Be careful with at

Biden administration begins canceling student loan debt for 804,000 borrowers

AltruBio raises $225 million to develop ulcerative colitis drug

Most antidepressants don't work on kids, teens, study finds

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Most antidepressants don't work on kids, teens, study finds

hotspot

hotspot

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

How one medical school became remarkably diverse

Brain technologies pose threats that are all too real, experts warn

Hepatitis C has a cure — but many Americans still lack access to it

Novel spinal cord stimulator treats paralysis without surgery

Bright Health sells Medicare Advantage business to Molina

Dozens dead from Maui wildfires: What we know about the victims

Virginia high school admissions case could be legal follow

Novo Nordisk touts Wegovy study, but still struggling with supply

focus

PBM executives asked to testify by House panel

Black vets could get higher VA benefits if race not used in lung test

Can gargling with Listerine treat gonorrhea of the mouth?

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Deliver public health messages at the right time

Novel spinal cord stimulator treats paralysis without surgery

leisure time

focus

explore

focus